The U.S. Food and Drug Administration is under pressure to boost oversight of online prescription drug promotions amid the rise of social media influencers and their potential to convey misinformation to vulnerable patients and impressionable teens.
Whether or not demands from some in the medical community and in Congress will spur new FDA guidance and greater enforcement, FDA-regulated companies should consider reviewing their policies and practices pertaining to influencers they engage, attorneys in the field say.
